Abstract: The present invention relates to compounds of Formula 1, and methods of use thereof, capable of entering macrophages. The invention further relates to compounds capable of modulating (for example inhibiting) the activity of the mammalian target of rapamycin (mTor), treating mTor-associated diseases, in particular, but not limited to, related to mTor in macrophages. The invention also relates to compounds capable of imaging mTor in a subject, in particular, but not limited to, mTor in macrophages.
Type:
Grant
Filed:
June 15, 2016
Date of Patent:
June 15, 2021
Assignee:
NANOPHAGIX LLC
Inventors:
Steven Jay Adelman, H. Donlon Skerrett, William A. Kinney